Agilent Technologies (A) recently received U.S. Food and Drug Administration approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic for several gastrointestinal cancers, highlighting the stock’s role in precision oncology diagnostics.

Even with FDA approval for its PD-L1 IHC 28-8 pharmDx assay and recent product launches in chromatography and security screening, Agilent Technologies’ share price is down 5.6% year to date, while the 1 year total shareholder return of 17.2% points to momentum building over a longer horizon.

If you are watching how diagnostics and biopharma tools are reshaping healthcare, it can be useful to see what else is moving by scanning 39 healthcare AI stocks

Agilent Technologies has slipped about 6% so far this year even as analysts and intrinsic value models sit more than 20% above the current US$130 share price. This raises the question of where fair value really lies within that gap.

Most Popular Narrative: 19.1% Undervalued

Agilent Technologies last closed at $130.26, while the most followed narrative anchors fair value at $161, pointing to a sizeable gap that hinges on future execution.

Strategic investments in higher-margin recurring revenue streams including consumables, software, services, and digital platforms are gaining traction, with CrossLab and services delivering consistent mid-single-digit growth and high customer satisfaction, indicating further margin expansion and greater earnings stability in future periods.

Want to see what sits behind that confidence in recurring revenue, higher margins, and future earnings power? The full narrative lays out the key forecasts in detail.

Result: Fair Value of $161 (UNDERVALUED)

However, there are still real pressure points for Agilent Technologies, including higher tariff related costs and the risk that slower academic funding could soften demand in key segments.

Another View On Agilent Technologies Valuation

The earlier narrative leans on discounted cash flows and analyst targets to frame Agilent Technologies as undervalued, yet the current P/E of 26x sits above the fair ratio of 23.5x, even though it is below both peer averages of 41.2x and the global Life Sciences average of 38.1x. That mix of relative cheapness and premium to the fair ratio leaves an open question: is the market paying up for quality or building in valuation risk that could matter if sentiment cools?

To see how this pricing gap looks when you line up Agilent Technologies directly against peers and the fair ratio the market could move toward, take a closer look at the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Reading this, you might sense growing optimism around Agilent Technologies. Consider moving quickly, reviewing the data for yourself, and weighing the 4 key rewards.

Looking For More Investment Ideas Beyond Agilent Technologies?

If Agilent Technologies has sparked your interest, do not stop there. Use the Simply Wall Street Screener to spot opportunities that could suit your strategy before others do.

• Target stability and income by reviewing companies built as potential income anchors with 9 dividend fortresses.
• Hunt for quality at a reasonable price by scanning companies that screen well on fundamentals using the 45 high quality undervalued stocks.
• Reduce unwanted surprises by focusing on companies with stronger resilience profiles through the 80 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.